The use of saphenous vein grafts (SVGs) in the surgical management of obstructive coronary artery disease remains high despite a growing understanding of their limitations in longevity. In contemporary practice, approximately 95% of patients receive one SVG in addition to a left internal mammary artery (LIMA) graft. The precise patency rates for SVGs vary widely in the literature, with estimates of up to 61% failure rate at greater than 10 years of follow-up. SVGs are known to progressively degenerate over time and, even if they remain patent, demonstrate marked accelerated atherosclerosis. Multiple studies have demonstrated a marked acceleration of atherosclerosis in bypassed native coronary arteries compared to non-bypassed arteries, which predisposes to a high number of native chronic total occlusions (CTOs) and subsequent procedural challenges when managing graft failure. Patients with failing SVGs frequently require revascularisation to previously grafted territories, with estimates of 13% of CABG patients requiring an additional revascularisation procedure within 10 years. Redo CABG confers a significantly higher risk of in-hospital mortality and, as such, percutaneous coronary intervention (PCI) has become the favoured strategy for revascularisation in SVG failure. Percutaneous treatment of a degenerative SVG provides unique challenges secondary to a tendency for frequent superimposed thrombi on critical graft stenoses, friable lesions with marked potential for distal embolization and subsequent no-reflow phenomena, and high rates of peri-procedural myocardial infarction (MI). Furthermore, the rates of restenosis within SVG stents are disproportionately higher than native vessel PCI despite the advances in drug-eluting stent (DES) technology. The alternative to SVG PCI in failed grafts is PCI to the native vessel, ‘replacing’ the grafts and restoring patency within the previously grafted coronary artery, with or without occluding the donor graft. This strategy has additional challenges to de novo coronary artery PCI, however, due to the high burden of complex atherosclerotic lesion morphology, extensive coronary calcification, and the high incidence of CTO. Large patient cohort studies have reported worse short- and long-term outcomes with SVG PCI compared to native vessel PCI. The PROCTOR trial is a large and randomised control trial aimed at assessing the superiority of native vessel PCI versus vein graft PCI in patients with prior CABG awaiting results. This review article will explore the complexities of SVG failure and assess the contemporary evidence in guiding optimum percutaneous interventional strategy.
In patients with fulminant tricuspid valve infective endocarditis precluded from cardiothoracic intervention based on comorbidities or clinical status, percutaneous vegetation debulking utilizing the AngioJet rheolytic catheter system appears a viable rescue option to achieve source control.
1 January 2025 in Cardiology Research and Practice
Background: Bioresorbable coronary stents (BRS) were designed with the aim of reducing the risk of late adverse events of permanent drug‐eluting stents (DES) by dissolving once vessel patency had been restored and the requirement for acute mechanical support resolved. Bioresorbable poly‐L‐lactic acid (PLLA) scaffold designs, while initially appearing as promising technology, were unsuccessful in widespread clinical use due to an observed high rate of late stent thrombosis. Magnesium‐based BRS (MgBRS) have provided an alternative to this original design and have shown promise in early‐phase clinical trials. This review aims to address the clinical question: How does the current safety and efficacy evidence for MgBRS in all patients requiring percutaneous coronary intervention compare with the randomised data assessing PLLA‐BRS and contemporary DES? Methods: Two parallel systematic reviews were performed using the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines, utilising MEDLINE, EMBASE and Web of Science: the first assessing clinical outcomes of all observational and randomised MgBRS trials, the second assessing clinical outcomes of PLLA‐BRS versus DES in randomised clinical trials. The primary safety and efficacy outcomes collected were cardiac death, target vessel failure (TVF) and stent thrombosis. Results: A total of 3582 MgBRS patients (24 trials), 6370 PLLA‐BRS and 5413 DES patients (16 trials) were included for analysis. Cardiac death was similar across all three stent designs in all time intervals. MgBRS performed similarly to contemporary DES and superiorly to PLLA‐BRS at 12‐ and 24‐month intervals with regard to TVF and stent thrombosis. Longer follow‐up was suggestive of a poorer performance of MgBRS relative to DES, although with limited patient numbers. Conclusion: MgBRS appear to perform similarly to DES and superiorly to PLLA‐BRS at 12 and 24 months in regard to key clinical safety and efficacy measures. Further randomised studies are required before recommending this technology for widespread clinical use over DES.
Background: The permanence of contemporary coronary stents is associated with chronic complications, particularly in-stent restenosis and stent thrombosis. Poly-L-lactic-acid-based bioresorbable stents were withdrawn given late stent thrombosis risk. Magnesium-based bioresorbable stents (MgBRS) have emerged as promising alternatives. This study documents the safety and efficacy profile of MgBRS generations. Methods: A systematic review was performed using EMBASE, MEDLINE and Web of Science (2007 to August 2025). Studies include individuals requiring percutaneous coronary intervention for coronary artery disease with MgBRS. Primary outcomes were cardiac death, definite/probable scaffold thrombosis and target vessel failure (TVF), organised into ≤12, ≤24, ≤36 and ≤60 months. The secondary outcome was late lumen loss (LLL). Results: Four MgBRS generations were identified: AMS-1, DREAMS 1G, Magmaris and Freesolve; and 25 studies were included. Cardiac death and stent thrombosis rates were under 1.0% up to 24 months for all, and 0% with Freesolve at 36 months. AMS-1 had the highest TVF rate at 44.4% at 12 months, improving to 3.6% at 36 months in Freesolve. Only Magmaris had 60-month data, showing 3.4% cardiac death, 2.7% stent thrombosis and 16.4% TVF rates. The data suggest improvement in 12-month LLL: DREAMS 1G (0.4 ± 0.3 mm), Magmaris (0.5 ± 1.1 mm) and Freesolve (0.2 ± 0.4 mm). Conclusions: Each successive generation demonstrated improvement in all studied outcomes since the underperformance of AMS-1. The favourable performance of Freesolve is comparable to contemporary drug-eluting stents. Results of randomised head-to-head trials are anticipated.